Uncovering the molecular mechanisms between heart failure and end-stage renal disease via a bioinformatics study

Rutao Bian1, Xuegong Xu1, Weiyu Li1

  • 1Zhengzhou Traditional Chinese Medicine Hospital, Zhengzhou, China.

Frontiers in Genetics
|January 27, 2023
PubMed

Insights

This study reveals crucial molecular links between heart failure (HF) and end-stage renal disease (ESRD), identifying common genes and pathways. These findings offer new therapeutic avenues for patients with both conditions.

Area of Science:

  • Bioinformatics
  • Genomics
  • Molecular Biology

Background:

  • Heart failure (HF) is a significant complication and cause of mortality in end-stage renal disease (ESRD) patients.
  • The underlying molecular mechanisms connecting HF and ESRD remain largely unclear.

Purpose of the Study:

  • To explore the molecular mechanisms and crosstalk between HF and ESRD using comprehensive bioinformatics analysis.
  • To identify common differentially expressed genes (DEGs) and potential therapeutic targets.

Main Methods:

  • Downloaded HF and ESRD datasets from the Gene Expression Omnibus (GEO) database.
  • Analyzed common DEGs using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set variation analysis (GSVA).
  • Utilized machine learning algorithms (RF, Boruta, LASSO, SVM-RFE) to identify hub genes and XGBoost for diagnostic efficacy evaluation. Analyzed immune cell infiltration and constructed regulatory networks.

Main Results:

  • Identified 68 common DEGs, suggesting immune response and inflammation as shared pathophysiological features.
  • Validated four hub genes (BCL6, CCL5, CNN1, PCNT) with diagnostic AUC > 0.8.
  • Found altered immune cell infiltration (macrophages, neutrophils, NK cells) in HF, with neutrophils correlating significantly with hub genes. Constructed mRNA-miRNA-TF regulatory networks and identified 10 potential drugs.

Conclusions:

  • This study elucidates significant molecular crosstalk between HF and ESRD.
  • Identified pivotal genes and pathways that could inform future clinical treatments and experimental research for these interconnected diseases.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
20
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
441
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
31